A randomized study comparing clinical efficacy and safety of thienamycin formamidine (MK0787)/renal dipeptidase inhibitor (MK0791) and cefazolin.
Twenty-one hospitalized patients with infectious diseases were randomly assigned to receive either thienamycin formamidine/renal dipeptidase inhibitor or cefazolin. Infections treated included septicaemia, pneumonia, osteomyelitis, pyelonephritis, cellulitis and cutaneous abscesses. All eleven patients treated with thienamycin formamidine/renal dipeptidase inhibitor responded well to therapy. One of the ten patients treated with cefazolin developed a superinfection with Pseudomonas aeruginosa. Side effects detected were minor in both groups.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001424:Bacterial Infections / Q000188:drug therapy*; D002437:Cefazolin / Q000627:therapeutic use*; D015377:Cilastatin; D002986:Clinical Trials as Topic; D003521:Cyclopropanes / Q000008:administration & dosage*; D004150:Dipeptidases / Q000037:antagonists & inhibitors*; D004359:Drug Therapy, Combination; D006801:Humans; D015378:Imipenem; D007668:Kidney / Q000201:enzymology*; D008875:Middle Aged; D011897:Random Allocation; D013845:Thienamycins / Q000008:administration & dosage*
D000900:Anti-Bacterial Agents; D003521:Cyclopropanes; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D004150:Dipeptidases; D002437:Cefazolin